The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia

NCT04398459 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Refractory/Relapsed Autoimmune Hemolytic Anemia

Interventions

DRUG: Ibrutinib

Sponsor

Institute of Hematology & Blood Diseases Hospital, China